

### ***Listing of the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

1 - 16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Currently amended)     ~~The antisense oligonucleotide of claim 17~~ An antisense oligonucleotide which is complementary to an NTP mRNA sequence, wherein said antisense oligonucleotide is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.

20. (Currently amended)     The antisense oligonucleotide of claim 17 ~~17~~ 19, which is deoxyribonucleic acid.

21. (Currently amended)     The antisense oligonucleotide of claim 17 ~~17~~ 19, which is deoxyribonucleic acid phosphorothioate.

22. (Currently amended)     The antisense oligonucleotide of claim 17 ~~17~~ 19, which is a derivative of a deoxyribonucleic acid or a deoxyribonucleic acid phosphorothioate.

23. (Currently amended) A pharmaceutical composition comprising the antisense oligonucleotide of claim ~~17~~ 19 and a pharmaceutically acceptable carrier.

24 - 30. (Canceled)

31. (Currently amended) ~~The ribonucleotide external guide nucleic acid molecule of claim 30 which~~ A ribonucleotide external guide nucleic acid molecule comprising a 10-mer nucleotide sequence fused to a 3'NCCA nucleotide sequence, wherein N is a purine, wherein said ribonucleotide external guide nucleic acid molecule is selected from the group consisting of SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.

32. (Currently amended) A pharmaceutical composition comprising the ribonucleotide of claim ~~30~~ 31 and a pharmaceutically acceptable carrier.

33 - 34. (Canceled)

35. (New) An antisense oligonucleotide, which is a 15 to 40 mer and is complementary to an NTP mRNA sequence corresponding to a region within nucleotides 150-1139 of SEQ ID NO:1, wherein said region includes one or more nucleotides selected from the group consisting of nucleotides 150, 194-195, 240-241, 243, 244, 255-256, 266-267, 269-271, 276, 279-280, 293-295, 338-340, 411, 459, 532-533, 591, 633-644, 795-797,

828, 853-854, 876-877, 883, 884-885, 898, 976, 979-980, 999, 1037, 1043-1044, 1092-1096, 1099, and 1116-1119 of SEQ ID NO:1.

36. (New) The antisense oligonucleotide of claim 35, which is deoxyribonucleic acid.

37. (New) The antisense oligonucleotide of claim 35, which is deoxyribonucleic acid phosphorothioate.

38. (New) The antisense oligonucleotide of claim 35, which is a derivative of a deoxyribonucleic acid or a deoxyribonucleic acid phosphorothioate.

39. (New) A pharmaceutical composition comprising the antisense oligonucleotide of claim 35 and a pharmaceutically acceptable carrier.